In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Building Medtronic Neuro by Trial: An Interview with Richard Kuntz, MD

Executive Summary

Medtronic is the acknowledged leader in one of the hottest device sectors-neurostimulation-but even this giant struggles with problems of limited market penetration. So Medtronic is bringing a new approach to this area: an aggressive clinical trials strategy to differentiate its products and drive physician adoption. Who better to run the business than a clinical trials expert? Richard Kuntz talks about future neuro opportunities and the current challenges facing device clinical trials.

You may also be interested in...



Medtronic: Doing Just What the Doctors Order

Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.

Medtronic: Doing Just What the Doctors Order

Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.

Profiles of COURAGE: Another Speed Bump for Stents or Flawed Trial?

Cardiologists and interventionalists continue to disagree on the importance of the COURAGE trial results. Academic disputes aside, the question for industry is whether this study will further drive down stent usage.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel